Tag
This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offerin
Sleep disordered breathing affects over half of patients with hypertrophic cardiomyopathy, correlating with worsening myocardial remodeling, diastolic dysfunction, and subclinical myocardial injury, underscoring the need for clinical trials
Intermediate effect genetic variants contribute significantly to hypertrophic cardiomyopathy risk and modify disease severity and outcomes, especially when coexisting with monogenic mutations.
This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the
The VALOR-HCM trial demonstrates that mavacamten sustains symptomatic improvement and significantly reduces septal reduction therapy (SRT) need over 128 weeks in severely symptomatic obstructive hypertrophic cardiomyopathy patients.
